Edit |   |
---|---|
Antigenic Specificity | CD85d (ILT4), Human |
Clone | REA184 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 |
Format | allophycocyanin (APC) conjugate |
Size | 100 tests in 1 mL |
Concentration | 1:11 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD85d (ILT4) Antibody, anti-human, APC, REAfinity™. Clone REA184 recognizes CD85d, also known as immunoglobulin-like transcript 4 (ILT4) or leukocyte Ig-like receptor 2 (LIR2). CD85d is an inhibitory immunoreceptor, expressed mainly on myelomonocytic lineage cells. | CD85d has four tandem Ig-like extracellular domains and three immunoreceptor tyrosine-based inhibitory receptor motifs in its cytoplasmic tails, which recruit the tyrosine phosphatase Src homology 2 domain containing phosphatase 1 (SHP-1). It has been shown that CD85d interacts with HLA-A, -B, -G1, and -E molecules as ligands. HLA-G expression is restricted to trophoblasts and thus interaction of CD85d with HLA-G is suggested to inhibit placental leukocytes, contributing to maternal tolerance of the fetal semiallograft. | Additional information: Clone REA184 displays negligible binding to Fc receptors. | |
Immunogen | n/a |
Other Names | LILRB2, ILT-4, LIR2, MIR-10 |
Gene, Accession # | Gene ID: 10288 |
Catalog # | 130-100-559 |
Price | $325 |
Order / More Info | CD85d (ILT4), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Shiroishi, M. et al. (2003) Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc. Natl. Acad. Sci. U.S.A. 100 (15): 8856-8861. | Shiroishi, M. et al. (2006) Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc. Natl. Acad. Sci. U.S.A. 103: 16412-16417. | Ristich, V. et al. (2007) Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells. Hum. Immunol. 68 (4): 264-271. |